600436 Zhangzhou Pientzehuang Pharmaceutical
- 237.49
- -0.13-0.05%
Zhangzhou Pientzehuang Pharmaceutical News
China Merchants Securities: The 24Q1 Chinese medicine sector has steadily overcome high base pressure, and profit levels and dividends have improved markedly
The traditional Chinese medicine industry was slightly under pressure due to high base pressure in the short term, but the level of profit and dividends performed well. In the context of policies encouraging the inheritance, innovation and development of traditional Chinese medicine, along with the reform of state-owned enterprises and the implementation of catalytic events such as the basic drug catalogue, the traditional Chinese medicine sector is still cost-effective.
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Has A Rock Solid Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Results were good overall, with
The third generation of medicine has lost 150 billion
Growth is still ongoing
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Investors Are Less Pessimistic Than Expected
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) as a stock to avoid entirely
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Shareholders Have Earned a 17% CAGR Over the Last Five Years
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) shareholders might be concerned after seeing the share price drop 12% in the last quarter. But that doesn't change the fact that shareholde
Is Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Latest Stock Performance A Reflection Of Its Financial Health?
Zhangzhou Pientzehuang Pharmaceutical's (SHSE:600436) stock is up by a considerable 15% over the past week. Given the company's impressive performance, we decided to study its financial indicators m
Pientzehuang Pharmaceutical's Profit Climbs 12.6% in 2023
Zhangzhou Pientzehuang Pharmaceutical (SHA:600436) booked a net profit attributable to shareholders of 2.78 billion yuan, or 4.61 yuan per share, in 2023, up 12.6% from 2.47 billion yuan, 4.10 yuan pe
Massive results kill! Many stocks have fallen to a standstill, and “Chinese Medicine Master” has not been able to hold up
Style interpretation is the ultimate
Is Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Trading At A 22% Discount?
Key Insights The projected fair value for Zhangzhou Pientzehuang Pharmaceutical is CN¥288 based on 2 Stage Free Cash Flow to Equity Zhangzhou Pientzehuang Pharmaceutical is estimated to be 22% under
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
600436.SH: PZH2108 tablets, an innovative drug to treat cancer pain, have completed phase I clinical trials
Pien Tsai (600436.SH) issued an announcement. Recently, the company's innovative drug PZH2108 tablets to treat cancer pain...
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Shares May Have Run Too Fast Too Soon
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 34x, you may consider Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) as a stock to potentially avo
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Ticks All The Boxes When It Comes To Earnings Growth
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometime
Those Who Invested in Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Five Years Ago Are up 212%
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) shareholders might be concerned after seeing the share price drop 13% in the last quarter. But in stark contrast, the returns over the last
Individual Investors Own 26% of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Shares but Private Companies Control 57% of the Company
Key Insights Significant control over Zhangzhou Pientzehuang Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions
[Instant Analysis of BT Financial Report] Pian Tzai's 2023 Third Quarter Report: Revenue and Net Profit Continue to Grow, and Net Cash Flow Has Decreased Sharply
This financial report was announced at 16:35:11, 2023-10-16 (stock code: 600436) is a company with a certain position in the pharmaceutical industry. Since its establishment in 1999, it has been restructured and founded, and listed and traded on the Shanghai Stock Exchange in 2003. The company was also certified by the Ministry of Commerce and the Ministry of Science and Technology, and became one of the first “China Time-honored Brand” enterprises. In the pharmaceutical industry, Pien Tsai Chung Company has a certain position in the industry. According to the 2023 three-quarter report, revenue for the reporting period was 2,555 million dollars, an increase of 16 over the same period last year.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Shares Could Be 23% Above Their Intrinsic Value Estimate
Key Insights Zhangzhou Pientzehuang Pharmaceutical's estimated fair value is CN¥217 based on 2 Stage Free Cash Flow to Equity Zhangzhou Pientzehuang Pharmaceutical's CN¥267 share price signals that
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Analysis
Price Target
No Data
